Literature DB >> 20706046

Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT.

Alexandra De Waele1, Sofie Van Binnebeek, Felix M Mottaghy.   

Abstract

A 57-year-old man with an adenocarcinoma of the prostate, presented with multiple lymph nodes in the para-aortic and right iliac region on computer tomography (CT). However, since the radiologic images were taken 3 weeks following an urosepsis, the differentiation between inflamed and metastatic lymph nodes is difficult. Thus, an integrated [C] choline positron emission tomography and computer tomography (PET/CT) was performed, showing multiple lymph nodes. The patient was staged as cT3N1M0 and treated with hormonal therapy. The choline PET/CT performed after hormonal treatment showed no more hypermetabolic lymph nodes. This case substantiate the hypothesis that choline PET/CT could be used to evaluate therapy response in prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706046     DOI: 10.1097/RLU.0b013e3181e9faf5

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

Review 1.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

2.  Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

Authors:  Giampiero Giovacchini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11       Impact factor: 9.236

Review 3.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

4.  Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.

Authors:  Rutger J Dost; Andor W J M Glaudemans; Anthonius J Breeuwsma; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

5.  Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

Authors:  J Amanie; H S Jans; M Wuest; N Pervez; A Murtha; N Usmani; D Yee; R Pearcey; B Danielson; S Patel; R Macewan; C Field; D Robinson; J Wilson; D Lewis; M Parliament; A J B McEwan
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

6.  Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study.

Authors:  Bhupesh Parashar; A Gabriella Wernicke; Samuel Rice; Joseph Osborne; Prabhsimranjot Singh; Dattatreyudu Nori; Shankar Vallabhajosula; Stanley Goldsmith; K S Clifford Chao
Journal:  Discov Med       Date:  2012-07       Impact factor: 2.970

7.  (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Authors:  Francesco Ceci; Paolo Castellucci; Marcelo Mamede; Riccardo Schiavina; Domenico Rubello; Chiara Fuccio; Valentina Ambrosini; Stefano Boschi; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

8.  Combined PET imaging and diffusion-weighted imaging of intermediate and high-risk primary prostate carcinomas with simultaneous [18F] choline PET/MRI.

Authors:  Axel Wetter; Felix Nensa; Marcus Schenck; Philipp Heusch; Thorsten Pöppel; Andreas Bockisch; Michael Forsting; Thomas W Schlosser; Thomas C Lauenstein; James Nagarajah
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

Review 9.  Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Authors:  Amarnath Challapalli; Eric O Aboagye
Journal:  Front Oncol       Date:  2016-02-29       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.